Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 6,665 shares at $0.71 ($5K) on 2019-01-14, disclosed to the SEC on 2019-01-16.
Open-market purchase of $5k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.71 | 4,399 | $3K | 66.3% |
| 2 | $0.70 | 2,266 | $2K | 33.7% |
| Total | $0.71 avg | 6,665 | $5K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |